BM8 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Biomarin Pharmaceutical Inc

Watchlist Manager

Watchlist

Price: 59.61 EUR -1.86% Market Closed

Market Cap: €11.3B

B	Biomarin Pharmaceutical Inc XMUN:BM8	US
S	Shell PLC AEX:SHELL	UK
B	Bankinter SA SWB:BAKA	ES
	ActiveOps PLC F:95D	UK
A	argenx SE F:1AEA	NL
T	Truist Financial Corp F:BBK	US
	Lithia Motors Inc F:LMO	US
B	Banco Bilbao Vizcaya Argentaria SA XHAM:BOY	ES

Profitability Summary

Biomarin Pharmaceutical Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

80%

Strong 3Y Average Gross Margin

80%

Gross Margin is Increasing

78% > 80%

Healthy Operating Margin

20%

Sustainable 3Y Average Operating Margin

18%

Operating Margin is Increasing

4% > 20%

Low Net Margin

Sustainable 3Y Average Net Margin

11%

Declining Net Margin

4% > 2%

Exceptional Free Cash Flow Margin

21%

Strong 3Y Average Free Cash Flow Margin

15%

Free Cash Flow Margin is Increasing

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.